Medicinal preparation for treating animal mycoplasma infection and application thereof

Abstract

The invention provides a medicinal preparation for treating animal mycoplasma infection and application thereof, and particularly relates to the technical field of application of veterinary chemical medicinal preparations. The active ingredients of the pharmaceutical preparation are an amino glycosamine compound and a transfer factor. The pharmaceutical preparation is prepared from a composition of an amino sugar amine compound, a transfer factor and one or more pharmaceutical adjuvants, or the pharmaceutical preparation is a mixed preparation of an amino sugar amine compound injection and a transfer factor injection. According to the pharmaceutical preparation, the amino glycosamine compound and the transfer factor are combined for injection, so that the dosage of antibiotics can be reduced, the treatment effect of poultry mycoplasma diseases can be improved, and the clinical application prospect is wide.

Description

Technical Field

[0001] The present invention relates to the technical field of application of veterinary chemical pharmaceutical preparations, and more particularly to a pharmaceutical preparation for treating mycoplasma infection in animals and application thereof. Background Art

[0002] Mycoplasma, also known as mycoplasma, is between the size of bacteria and viruses. It is a type of prokaryotic organism with a diameter of about 0.11 μm and only a cell membrane without a cell wall. At present, the mycoplasmas that have a greater impact on poultry farming are mainly Mycoplasma gallisepticum (MG), Mycoplasma synoviae (MS) and Mycoplasma meleagridis (MM). MG is the main cause of respiratory diseases in poultry. MS can cause subclinical respiratory symptoms, arthritis, synovitis, air sac inflammation, genital tract inflammation and egg tip syndrome in poultry. Mycoplasma meleagridis causes embryonic death in turkeys, leading to mild respiratory infections, bone abnormalities and decreased growth rates in turkeys. According to epidemiological surveys, the average positive infection rate of mycoplasma in chicken flocks is 70% to 80%. Chickens of all ages can be infected, and chickens of different breeds have similar resistance. Except for some SPF chicken farms, it can be said that any chicken farm is troubled by mycoplasma infection.

[0003] Mycoplasma is mainly transmitted through the air. Another important transmission method is vertical transmission through breeder chickens, which causes mycoplasma in chicks or makes them weak after hatching. The third transmission method is through certain chicken embryo live vaccines or yolk antibody inactivated vaccines. The chicken embryos or yolks used to make vaccines carry mycoplasma viruses, which cause mycoplasma transmission during vaccination. The disease has a high incidence rate, a long course of disease, and slow recovery. Once the disease appears in a chicken farm, in addition to the harm it causes, it can also induce a variety of viral and bacterial respiratory diseases, making the prevention and control of the disease more complicated. Mycoplasma has no cell wall and is easy to develop drug resistance. General drug treatment is ineffective. Even if effective drugs are used for treatment, it only has a certain effect in the short term and cannot be completely cured. It can relapse after stopping the drug. The widespread prevalence of this disease in my country has caused immeasurable economic losses to the poultry industry and is a potential killer of chicken health. According to statistics, after chickens are infected with Mycoplasma gallisepticum, the egg production rate of laying hens will drop by 20%-40%, the feed conversion rate will decrease by about 21%, the weight of broilers will decrease by about 38%, the carcass quality will also decrease, and the cost of drug use will increase, resulting in serious economic losses and seriously affecting the sustainable development of the poultry industry.

[0004] Aminoglycosides are glycoside antibiotics formed by aminosugar and aminocyclitol connected by oxygen bridges. Commonly used in clinical practice include streptomycin, kanamycin, gentamicin, neomycin, amikacin, gentamicin, spectinomycin, etc. Kanamycin is an aminoglycoside antibiotic produced by Streptomycekanamyceticus. It has a broad antibacterial spectrum and strong bactericidal effect. It has inhibitory effects on both Gram-positive and Gram-negative bacteria and has post-antibiotic effects (PAE) on many pathogenic bacteria. Kanamycin is an inhibitor of protein synthesis. Its main mechanism of action is to hinder the formation of complexes required for protein synthesis in the initial stage of protein synthesis; in the protein formation stage, it interacts with RNA 30S subunits, causing errors in gene coding; in the termination stage of protein synthesis, it inhibits the action of termination factors, so that the synthesized protein cannot be separated from RNA normally. Kanamycin is a commonly used drug in the poultry and livestock farming industry. It is widely used to treat infections caused by various bacteria, such as Escherichia coli, drug-resistant Staphylococcus aureus, cocci, Klebsiella pneumoniae and Shigella dysenteriae. However, in the breeding process, the irregular use of antibiotics leads to increased drug resistance and increased drug dosage, which not only greatly increases the breeding cost, but also poses a hidden danger to food safety. The development of new low-cost solutions is the key to the healthy development of the poultry farming industry.

[0005] Transfer factor (TF) is a type of small molecule dialyzable substance released by immune-active T lymphocytes in white blood cells. TF carries the specific immune information of sensitized lymphocytes and can induce T cells to transform into specific sensitized lymphocytes in the recipient. Therefore, it can specifically and passively transfer the donor's cellular immunity to the recipient, so that the recipient can obtain specific cellular immune function, that is, transfer and expand cellular immunity. TF is a polypeptide substance containing a variety of amino acids, with a small molecular weight, no pyrogen, no antigenicity, no toxic side effects and no species difference. It is a new and safe immune preparation. TF can non-specifically enhance the cellular immune function of the recipient; it can specifically transfer a certain cellular immune function of the donor to the recipient so that it has this cellular immune function; it also has the ability to promote the binding of monocytes to Ig complexes; and it has the function of inducing the release of interferon.

[0006] At present, TF has been successfully used as an adjuvant or applied to the early treatment of viral, parasitic, fungal and bacterial infections, as well as for the treatment of immunodeficiency, tumors, allergies and autoimmune diseases. Animals highly immunized with a certain antigen are used to prepare a large number of specific TFs for the prevention and treatment of infectious diseases, especially viral infectious diseases. It has a rapid effect, significant effect, no drug residue, and no toxic side effects. Specific TF is divided into anti-tumor specific TF, anti-microbial (including virus, bacteria, fungus, etc.) TF and other specific TF. Japan Bio-Health Company immunizes dairy cows with bacterial and viral antigens that cause major infectious diseases in chickens, and prepares specific TF from colostrum, which is used to prevent and treat diseases caused by pathogens such as Staphylococcus aureus, Streptococcus , Clostridium perfringens, Escherichia coli, Pseudomonas aeruginosa, Salmonella, Haemophilus parahaemolyticus, Mycoplasma, Newcastle disease, infectious bronchitis virus (IBV), and avian infectious bursal disease virus (IBDV). The effect is good and the product has been put on the market for a long time.

[0007] The breeding field is in urgent need of a pharmaceutical preparation that can reduce the dosage of antibiotics and improve the therapeutic effect of poultry mycoplasma diseases. The present invention combines aminoglycosamine compounds with transfer factors to treat animal diseases caused by mycoplasma infection, aiming to effectively solve the long-standing problem of mycoplasma infection faced by farmers. Summary of the invention

[0008] The present invention aims to solve the problems in the prior art and provides a pharmaceutical preparation for treating mycoplasma infection in animals and application thereof.

[0009] In a first aspect, the present invention provides a pharmaceutical preparation for treating mycoplasma infection in animals, wherein the pharmaceutical preparation is prepared by using a combination of active ingredients aminoglycosamine compounds and transfer factors and one or more pharmaceutical excipients.

[0010] Preferably, the ratio of the aminoglycosamine compound to the transfer factor is 0.5-5:1.

[0011] More preferably, the ratio of the aminoglycosamine compound to the transfer factor is 0.5-2:1.

[0012] The aminoglycosamine compound is selected from kanamycin or its salt, spectinomycin or its salt, neomycin or its salt, gentamicin or its salt, streptomycin or its salt, amikacin or its salt, and metronidazole or its salt.

[0013] Preferably, the aminoglycosamine compound is selected from kanamycin or its salt, spectinomycin or its salt, gentamicin or its salt.

[0014] The transfer factor is selected from the group consisting of pig spleen transfer factor, chicken spleen transfer factor, sheep placenta transfer factor, and cow milk transfer factor.

[0015] The pharmaceutical excipients include antioxidants, pH regulators, metal ion chelating agents and stabilizers.

[0016] The weight proportions of the components in the pharmaceutical preparation are: 2.0-60.0 parts of active ingredient, 0.01-3.0 parts of antioxidant, 0.01-4.0 parts of metal ion complexing agent, 0.01-5.0 parts of pH adjuster, 0.1-30.0 parts of stabilizer, and the balance is water for injection.

[0017] Preferably, the weight proportions of the components in the pharmaceutical preparation are: 5.0-50.0 parts of active ingredient, 0.05-2.0 parts of antioxidant, 0.05-3.0 parts of metal ion complexing agent, 0.02-4.0 parts of pH adjuster, 1.0-20.0 parts of stabilizer, and the balance is water for injection.

[0018] More preferably, the weight proportions of the components in the pharmaceutical preparation are: 15.0-45.0 parts of active ingredient, 0.1-1.0 parts of antioxidant, 0.1-1.2 parts of metal ion complexing agent, 0.04-2.0 parts of pH adjuster, 2.0-10.0 parts of stabilizer, and the balance is water for injection.

[0019] The antioxidant is one or more of monothioglycerol, sodium pyrosulfite, sulfite, metasulfite, sodium thiosulfate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, glycine, cysteine, methionine, glutathione, thiourea, edetic acid, vitamin C, vitamin E, vitamin B2, L-cysteine ​​hydrochloride, L-methionine, and L-lysine.

[0020] Preferably, the antioxidant is one or more of monothioglycerol, sodium pyrosulfite, L-cysteine ​​hydrochloride, sodium bisulfite, sodium thiosulfate, and vitamin C.

[0021] More preferably, the antioxidant is selected from monothioglycerol, sodium thiosulfate, L-cysteine ​​hydrochloride, sodium sulfite, sodium metabisulfite.

[0022] The metal ion complex is one or more of ethylenediaminetetraacetic acid or its sodium salt, sodium triphosphate, disodium nitrilotriacetate, gluconic acid, and sodium tripolyphosphate.

[0023] Preferably, the metal ion complex is one or more of EDTA, EDTA-2Na, sodium triphosphate, and sodium tripolyphosphate.

[0024] More preferably, the metal ion complex is selected from EDTA-2Na and sodium triphosphate.

[0025] The pH regulator is one or more of citric acid, malic acid, tartaric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, acetic acid, phosphoric acid, lactic acid, succinic acid, oxalic acid, caprylic acid, methanesulfonic acid, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, and basic amino acids.

[0026] Preferably, the pH adjuster is one or more of citric acid, malic acid, hydrochloric acid, sodium bicarbonate, tartaric acid, sodium hydroxide, lactic acid, and succinic acid.

[0027] More preferably, the pH adjuster is one or more of citric acid, malic acid, sodium bicarbonate, tartaric acid, and succinic acid.

[0028] The stabilizer is one or more of glycerol, propylene glycol, acetamide, docusate sodium, polysorbate, pvp-k30, pEG400, and mannitol.

[0029] Preferably, the stabilizer is one or more of glycerol, docusate sodium, propylene glycol, acetamide, mannitol, and pEG400.

[0030] More preferably, the stabilizer is selected from glycerol, propylene glycol, acetamide, docusate sodium, mannitol, and pEG400.

[0031] The stabilizer is used to ensure that the biological activity of the transfer factor remains unchanged and the quality is stable after the transfer factor is prepared into a compound preparation.

[0032] A preferred formulation of a pharmaceutical preparation for treating mycoplasma infection in animals is as follows: 10-20 parts of kanamycin sulfate, 10-20 parts of transfer factor, 0.2-0.6 parts of antioxidant, 0.1-0.2 parts of metal ion complex, 0.1-0.4 parts of pH regulator, 2-10 parts of stabilizer, and the balance is water for injection.

[0033] A more preferred formulation of a pharmaceutical preparation for treating mycoplasma infection in animals is: 10-20 parts of kanamycin sulfate, 10-20 parts of transfer factor, 0.2-0.6 parts of thioglycerol, 0.1-0.2 parts of a metal ion complex, 0.1-0.4 parts of a pH regulator, 1-5 parts of propylene glycol, 1-5 parts of acetamide, and the remainder is water for injection.

[0034] In a second aspect, the present invention provides a pharmaceutical preparation for treating mycoplasma infection in animals, wherein the pharmaceutical preparation is a mixed preparation of an aminoglycosamine compound injection and a transfer factor injection.

[0035] Preferably, the aminoglycosamine compound injection is prepared by a pharmaceutical method using an aminoglycosamine compound and one or more pharmaceutical excipients.

[0036] Preferably, the transfer factor injection is prepared from a transfer factor extract by a pharmaceutical method.

[0037] Preferably, the mixed preparation of the aminoglycosamine compound injection and the transfer factor injection is used by injecting immediately after mixing.

[0038] In a third aspect, the present invention provides a use of a pharmaceutical preparation for treating animal mycoplasma infection in the preparation of a medicament for treating poultry Mycoplasma synoviae infectious diseases or Mycoplasma gallisepticum infectious diseases, preferably for treating poultry Mycoplasma synoviae infectious diseases.

[0039] Preferably, the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is an injection.

[0040] Preferably, the animal of the present invention is poultry, preferably chicken.

[0041] The beneficial effects of the present invention are:

[0042] 1. The pharmaceutical preparation of the present invention combines aminoglycosamine compounds and transfer factors for injection, which can not only reduce the dosage of antibiotics, but also improve the therapeutic effect of poultry mycoplasma diseases, maintain animal production capacity, and reduce economic losses.

[0043] 2. The pharmaceutical preparation of the present invention is injected in the form of a composition, and a one-time injection can greatly reduce animal stress and economic losses. At the same time, it is easy to operate and reduces labor costs.

[0044] 3. The pharmaceutical preparation of the present invention uses the preferred antioxidant, stabilizer and pH adjuster, which work synergistically to not only ensure the stability of the aminoglycoside compound, but also ensure that the transfer factor is not inactivated, thereby ensuring the efficacy of the drug and the stability of the quality.

[0045] 4. The preparation method of the pharmaceutical preparation of the present invention is simple and has great clinical use and promotion value. DETAILED DESCRIPTION

[0046] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0047] Unless otherwise specified, the raw materials and reagents used in the following examples are commercially available or can be prepared by known methods.

[0048] Example 1

[0049] The composition of the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is as follows:

[0050] Components Dosage (g / 100ml) Kanamycin Sulfate 10g Transfer factor (purified extract) 10g Thioglycerol 0.2g Sodium triphosphate 0.1g Citric acid 0.2g Propylene glycol 5g Acetamide 5g Water for injection Add to 100ml

[0051] According to the above prescription composition, the injection of kanamycin sulfate and transfer factor is prepared, and the preparation steps are as follows: weigh 40g of water for injection, add sodium triphosphate and stir to dissolve, add acetamide and kanamycin sulfate successively to dissolve, then add propylene glycol and mix well, adjust the pH to 4.0-7.0 with citric acid, add thioglycerol and transfer factor and stir to mix well, and dilute to the scale with water for injection. After mixing, filter through 0.45μm and 0.22μm filter membranes respectively, and fill.

[0052] Example 2

[0053] The composition of the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is as follows:

[0054]

[0055]

[0056] According to the above prescription composition, the injection of kanamycin monosulfate and transfer factor is prepared, and the preparation steps are as follows: weigh 40g of water for injection, add EDTA-2Na and stir to dissolve, add kanamycin monosulfate to dissolve, adjust the pH to 4.0-7.0 with tartaric acid, then add thioglycerol, propylene glycol, mannitol, and transfer factor and stir to mix, and finally dilute to the scale with water for injection. After mixing, filter through 0.45μm and 0.22μm filter membranes respectively, and fill.

[0057] Example 3

[0058] The composition of the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is as follows:

[0059] Components Dosage (g / 100ml) Kanamycin monosulfate 20g Transfer factor (purified extract) 20g L-Cysteine ​​hydrochloride 0.6g EDTA 0.2g Succinic acid 0.4g Docusate Sodium 0.2g Acetamide 2g Water for injection Add to 100ml

[0060] According to the above prescription composition, the injection of kanamycin monosulfate and transfer factor is prepared, and the preparation steps are as follows: weigh 40g of water for injection, add EDTA, L-cysteine ​​hydrochloride, and sodium docusate to dissolve, then add kanamycin monosulfate to dissolve, then add acetamide to mix, adjust the pH to 4.0-7.0 with succinic acid, then add transfer factor to mix, and finally dilute to the scale with water for injection. After mixing, filter through 0.45μm and 0.22μm filter membranes respectively, and fill.

[0061] Example 4

[0062] The composition of the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is as follows:

[0063]

[0064]

[0065] According to the above prescription composition, the injection of kanamycin sulfate and transfer factor is prepared, and the preparation steps are as follows: weigh 40g of water for injection, add sodium thiosulfate and EDTA, stir and dissolve respectively; add kanamycin sulfate to dissolve, add glycerol and mix well, adjust the pH to 4.0-7.0 with succinic acid, add transfer factor and stir and mix well, and dilute to the scale with water for injection. After mixing, filter through 0.45μm and 0.22μm filter membranes respectively, and fill.

[0066] Example 5

[0067] The composition of the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is as follows:

[0068] Components Dosage (g / 100ml) Spectinomycin 5g Transfer factor (purified extract) 10g Sodium sulfite 0.1g EDTA 0.5g Malic Acid 0.04g glycerin 10g Water for injection Add to 100ml

[0069] According to the above prescription composition, the injection of spectinomycin and transfer factor is prepared, and the preparation steps are as follows: weigh 40g of water for injection, add sodium sulfite and EDTA, stir and dissolve them respectively; add spectinomycin to dissolve, add glycerol and mix well, adjust the pH to 4.0-7.0 with malic acid, add transfer factor and stir and mix well, and dilute to the scale with water for injection. After mixing, filter through 0.45μm and 0.22μm filter membranes respectively, and fill.

[0070] Example 6

[0071] The composition of the pharmaceutical preparation for treating mycoplasma infection in animals of the present invention is as follows:

[0072] Components Dosage (g / 100ml) Gentamycin (sulfate) 15g Transfer factor (purified extract) 30g Sodium metabisulfite 1.0g EDTA-2Na 1.2g Sodium bicarbonate 2.0g pEG400 2.0g Water for injection Add to 100ml

[0073] According to the above prescription composition, the injection of gentamicin and transfer factor is prepared, and the preparation steps are as follows: weigh 50g of water for injection, add sodium pyrosulfite and EDTA-2Na, stir and dissolve them respectively, add gentamicin to dissolve, add pEG400, adjust the pH to 4.0-6.0 with sodium bicarbonate, add transfer factor, stir and mix, and dilute to the scale with water for injection. After mixing, filter through 0.45μm and 0.22μm filter membranes respectively, and fill.

[0074] Comparative Example 1

[0075] The injection solution was prepared according to the method of Example 2 of patent CN 102552118A, and a certain amount of transfer factor was added. The formula was as follows:

[0076] Components Dosage (g / 100ml) Kanamycin Sulfate 35g Transfer factor (purified extract) 20g 5M concentrated sulfuric acid 20g Sodium metabisulfite 0.15g Edetate Disodium 0.013g Disodium hydrogen phosphate 0.2g Sodium Citrate 0.4g Water for injection Add to 200ml

[0077] Take kanamycin sulfate, add 50% water for injection, add 20g of 5 molar sulfuric acid to dissolve under constant stirring, then add sodium metabisulfite, disodium edetate and disodium hydrogen phosphate, stir thoroughly until dissolved, adjust the pH to 5.0-7.0 with 5 molar sulfuric acid, then add 0.02g of activated carbon and stir for 55 minutes, filter and decarbonize, finally add transfer factor and the remaining water for injection, filter through 0.45μm and 0.22μm filter membranes, and fill.

[0078] Example 7 Study on the stability of the pharmaceutical preparation of the present invention

[0079] The stability of active ingredients in medicines is related to clinical effects. Especially under high temperature conditions, active ingredients are easily inactivated. In order to ensure product quality, the stability of drug preparations under high temperature conditions was investigated. The method is: the drug preparations in each example are placed at 60°C for 10 days to investigate the stability of the active ingredients. The specific test results are shown in Table 1:

[0080] Table 1 Drug preparation stability results

[0081]

[0082]

[0083] From the stability results in the above table, it can be seen that the injections prepared according to Examples 1-6, when placed at 60°C for 10 days, have almost no change in the content of aminoglycosamine compounds and transfer factors, and are of stable quality, especially the injection of Example 1 has the best stability. However, for the injection of Comparative Example 1, the transfer factor quality stability is relatively poor under high temperature conditions.

[0084] Example 8 Clinical effect test of the preparation of the present invention

[0085] 180 test chickens were randomly divided into 6 groups, 30 in each group, and weighed separately. The experimental groups and drug treatments are shown in Table 2.

[0086] The tested chickens were inoculated with Mycoplasma gallisepticum synoviae (containing 1×10 9 ccu / ml), the dosage was 0.3mL / bird, and the negative control group (healthy control group) experimental chickens were injected with normal saline in the trachea, the dosage was 0.3mL / bird. Clinical observation was carried out every day after artificial infection, and the mental state, appetite and respiratory status of the chickens were recorded. 24h after inoculation with the standard strain of Mycoplasma gallisepticum synoviae, except for the negative control group, the chickens in other infection groups gradually began to show symptoms such as coughing, panting, mental depression, decreased appetite, rapid breathing, and open mouth breathing.

[0087] At this time, each group of animals was given drugs according to Table 2, and the drugs were given once. After the drugs were given, the clinical reactions of the chickens were observed every day for 14 consecutive days. After the test, each chicken was weighed and dissected, and the macroscopic changes of the air sac and lungs were observed, and the air sac damage was scored. The mortality rate, cure rate, effective rate, relative weight gain rate, and air sac damage reduction rate were calculated.

[0088] Table 2 Experimental groups and treatment methods

[0089]

[0090] The test results are as follows:

[0091] Table 3 Test results

[0092] Group No. mortality rate Cure rate Efficiency Average airbag rating Airbag injury reduction rate Relative weight gain Negative control group 0 / / 0 / / Positive control group 8 / 30 0 / 30 0 / 30 4.58 23.4％ 84.2％ Test Group A 0 30 / 30 30 / 30 0 100.0％ 105.7％ Test Group B 7 / 30 5 / 30 15 / 30 2.16 36.0％ 90.3％ Test Group C 5 / 30 7 / 30 12 / 30 3.72 45.3％ 89.1％ Test Group D 1 / 30 25 / 30 27 / 30 0.13 96.4％ 94.7％

[0093] It can be seen from the above test results that the pharmaceutical preparation prepared according to Example 1 can effectively treat diseases caused by Mycoplasma gallisepticum infection, and the use effect is better than using a single preparation.

[0094] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A pharmaceutical preparation for treating mycoplasma infection in animals, characterized in that: The active ingredients of the pharmaceutical preparation are aminoglycosamine compounds and transfer factors; the pharmaceutical preparation is prepared from a combination of the active ingredients and one or more pharmaceutical excipients; wherein the dosage ratio of the aminoglycosamine compounds to the transfer factors is 0.5-5:

1.

2. The pharmaceutical preparation according to claim 1, characterized in that The aminoglycosamine compound is one or more of kanamycin or its salt, spectinomycin or its salt, neomycin or its salt, gentamicin or its salt, streptomycin or its salt, amikacin or its salt, and metronidazole or its salt.

3. The pharmaceutical preparation according to claim 1, characterized in that The transfer factor is one or more of pig spleen transfer factor, chicken spleen transfer factor, sheep placenta transfer factor and cow milk transfer factor.

4. The pharmaceutical preparation according to claim 1, characterized in that The pharmaceutical excipients in the pharmaceutical preparation include antioxidants, pH regulators, metal ion chelating agents, and stabilizers; the weight proportions of the components in the pharmaceutical preparation are: 2.0 to 60.0 parts of active ingredients, 0.01 to 3.0 parts of antioxidants, 0.01 to 4.0 parts of metal ion chelating agents, 0.01 to 5.0 parts of pH regulators, 0.1 to 30.0 parts of stabilizers, and the balance is water for injection.

5. The pharmaceutical preparation according to claim 4, characterized in that The antioxidant is one or more of monothioglycerol, sodium pyrosulfite, sulfite, metasulfite, sodium thiosulfate, ascorbic acid, butylated hydroxytoluene, butylated hydroxyanisole, glycine, cysteine, methionine, glutathione, thiourea, edetic acid, vitamin C, vitamin E, vitamin B2, L-cysteine ​​hydrochloride, L-methionine, and L-lysine.

6. The pharmaceutical preparation according to claim 4, characterized in that The metal ion complex is one or more of ethylenediaminetetraacetic acid or its sodium salt, sodium triphosphate, disodium nitrilotriacetate, gluconic acid, and sodium tripolyphosphate.

7. The pharmaceutical preparation according to claim 4, characterized in that The pH regulator is one or more of citric acid, malic acid, tartaric acid, hydrochloric acid, sodium hydroxide, potassium hydroxide, acetic acid, phosphoric acid, lactic acid, succinic acid, oxalic acid, caprylic acid, methanesulfonic acid, sodium bicarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate, and basic amino acids.

8. The pharmaceutical preparation according to claim 4, characterized in that The stabilizer is one or more of glycerol, propylene glycol, acetamide, docusate sodium, polysorbate, pvp-k30, pEG400, and mannitol.

9. A pharmaceutical preparation for treating mycoplasma infection in animals, characterized in that: The pharmaceutical preparation is a mixed preparation of aminoglycosamine compound injection and transfer factor injection; the aminoglycosamine compound injection is prepared by aminoglycosamine compound and one or more pharmaceutical excipients through a pharmaceutical method; the transfer factor injection is prepared by a transfer factor extract through a pharmaceutical method.

10. Use of the pharmaceutical preparation for treating animal mycoplasma infection according to any one of claims 1 to 9 in a drug for treating Mycoplasma synoviae infectious diseases or Mycoplasma gallisepticum infectious diseases.

Images